Objectives: Colistin and carbapenem are two lines of last-resort antibiotics against lethal infections caused by MDR Gram-negative pathogens. The emergence of carbapenemase-positive Escherichia coli with colistin resistance poses a serious threat to public health worldwide. Here we report, for the first time (to the best of our knowledge), a novel combination therapy used for the treatment of E. coli co-producing MCR-1 and NDM-5.
Introduction
The increasing incidence of carbapenem-resistant Enterobacteriaceae (CRE) poses a great threat to global public health, and has resulted in increased morbidity, mortality, length of hospitalization and healthcare costs. 1, 2 In particular, CRE that produce New Delhi metallo-b-lactamase (NDM) usually exhibit resistance to almost all the currently available b-lactam antibiotics. Consequently, the treatment of infections caused by these resistant strains is frequently limited to antibiotics such as polymyxins, fosfomycin, tigecycline and rifampicin, used as monotherapy or in combination therapy. Polymyxins, e.g. colistin, are now recognized as the lastresort antibiotics to treat serious infections caused by CRE, and are often used as the core antibiotics in combination treatment regimens. 3 Unfortunately, a plasmid-mediated colistin resistance gene (mcr-1) has recently been reported in Enterobacteriaceae. 4 The emergence of the mcr-1 gene was subsequently identified in various isolates from diverse sources worldwide. 5, 6 Worryingly, carbapenem-and colistin-resistant Escherichia coli isolates that carry the mcr-1 gene have also been detected from humans and animals, [7] [8] [9] [10] raising a serious challenge to public health. The rapid emergence of the mcr-1 gene among carbapenemresistant E. coli isolates means that infected patients may have only extremely limited antibiotic options. Fortunately, the mcr-1 gene commonly mediates only low-level resistance to colistin, resulting in only 2-to 4-fold increments above the susceptibility breakpoint. 4 Therefore, combination therapy with an additional agent is considered to be a potential mechanism for the effective administration of colistin. Several previous investigations have revealed the synergistic effect of colistin in combination with meropenem, rifampicin or b-lactams commonly used against Acinetobacter baumannii and Pseudomonas aeruginosa. [11] [12] [13] In this study, we demonstrated both in vitro and in vivo increased bacterial killing activities of colistin when combined with amikacin against E. coli isolates co-producing NDM-5 and MCR-1. These study isolates included a representative of the pandemic clonal complex ST648, which has contributed to numerous severe extraintestinal pathogenic E. coli (ExPEC) infections (including urinary tract infections, bacteraemia and cases of meningitis, in both humans and animals). 14, 15 Our results might contribute to the discovery of an effective treatment regimen against colistin and carbapenem-resistant E. coli infections.
Materials and methods

Bacterial strains
Four well-characterized E. coli isolates, including one colistin-susceptible E. coli strain (2630/ST3902) and three colistin-resistant E. coli strains carrying mcr-1 (1320/ST648; 2610/ST101; 2121/ST156), were used in this study (Table 1 ). E. coli strains 2121 and 2610 were isolated from rectal swabs of 6-month-old cats with fever and diarrhoea, while strains 1320 and 2630 were isolated from rectal swabs of 1-month-old Muscovy ducks with colibacillosis in the Animal Diagnostic Laboratory of South China Agricultural University. 7, 16 PCR and sequencing assays confirmed that all strains produced NDM-5 carbapenemase, and exhibited relatively high meropenem MICs (16 mg/L). These E. coli strains belonged to four different clonal types, as determined previously by PFGE. 7, 16 All E. coli were identified using a MALDI-TOF/MS system (Axima-Assurance-Shimadzu).
Antibiotics and in vitro susceptibility testing
Colistin and amikacin powders were obtained from Sigma-Aldrich and prepared as fresh stock solutions in sterile distilled water or culture medium at the start of testing. For each E. coli isolate, colistin MIC was determined in the presence of 0, 1, 2 and 4 mg/L amikacin according to a modified broth microdilution method. 17 All isolates were tested in triplicate to ensure reproducibility. CAMHB (Oxoid Ltd, Basingstoke, UK) was used in all experiments. Non-carbapenemase-producing E. coli strain ATCC 25922 served as a quality-control strain. MIC results were interpreted according to CLSI breakpoint recommendations. 18 
Static time-kill experiments
The in vitro time-kill curve assay was used to evaluate the effect of colistin alone and in combination with amikacin on the 48 h time course of bacterial population dynamics as previously described. 19 In brief, broth cultures of freshly plated bacteria were grown to the logarithmic phase overnight and diluted into fresh CAMHB, giving an initial inoculum of approximately 10 6 or 10 8 cfu/mL. The testing procedure consisted of a 7-by-4 exposure array of colistin (0, 0.5, 1, 2, 4, 8 and 16 mg/L) and amikacin (0, 1, 2 and 4 mg/L), with each agent tested alone and in combination over 48 h of incubation. Thus, for each of the two inoculum sizes, there was 1 control test with no drug, 9 tests with each drug alone at the various concentrations employed and 18 tests of drug combinations. In total 28 regimens were determined against each E. coli isolate.
Aliquots of 100 lL of each sample were withdrawn at 0, 1, 3, 6, 9, 12, 24, 27, 30, 33 and 48 h after 37 C incubation, and serially diluted 10-fold in sterile normal saline. Subsequently, 100 lL of each dilution was removed and dropped onto antibiotic-free tryptic soy agar (TSA) plates for viable count enumeration. Results were expressed as cfu/mL, with a limit of detection (LOD) of 10 cfu/mL.
In vitro pharmacodynamic (PD) analysis
The microbiological effect (E) of each concentration of each drug alone and of each of the drug combinations was determined using the log change method, comparing the change in log 10 cfu/mL from 0 h (cfu 0h ) to 48h (cfu 48h ), such that the log 10 -transformed change (Dlog 10 ) was Dlog 10 " log 10 (cfu 48h ) # log 10 (cfu 0h ). The relationship between colistin concentration and antibacterial effect (Dlog 10 ) against E. coli isolates for each amikacin concentration was plotted according to static time-kill data. The colistin concentration-effect relationships were then modelled using the inhibitory sigmoid E max model derived from a Hill-type equation as follows:
, where E 0 is the log 10 change of bacterial count in the absence of colistin, E max is the maximal antibacterial effect, C is the concentration of colistin, EC 50 is the concentration required to achieve 50% of maximal effect and N is the Hill coefficient that described the slope of the concentration-effect curve. These data were analysed using the non-linear WinNonlin regression program (version 6.1, Pharsight, USA). The coefficient of determination (r 2 ) was used to estimate the variance of regression for PD analysis.
Statistical analysis
A non-parametric statistical test (Friedman's ANOVA) was used to analyse the PD parameters, including EC 50 and E max , and to study the effect of colistin in combination with increasing amikacin concentrations. Differences in PD parameter values between low and high inoculum sizes (10 6 and 10 8 cfu/mL) were evaluated for each E. coli isolate by a hypothesis test with Fisher's test. All statistical analyses were performed using RStudio (version 0.99.903, RStudio Inc., Boston, MA, USA). Dataset comparisons with differences of P values of ,0.05 were considered statistically significant. Zhou et al.
Pharmacokinetics (PK) and antibiotic concentration measurements
Single-dose PK studies were performed in thigh-infected neutropenic mice after intraperitoneal administration of colistin (5 and 7.5 mg/kg) and amikacin (7.5 mg/kg) as described previously. 20 Multiple blood samples were collected by retro-orbital puncture after antibiotic injection over 8 h. The drug concentrations in plasma were determined using an LC-MS/MS assay. 21, 22 The limits of quantification of colistin and amikacin were 0.05 and 0.1 mg/L, respectively. Both inter-day and intra-day coefficients of variation were within 10.5%. To obtain the PK parameters, the plasma time-concentration data were subjected to non-compartmental analysis (WinNonlin, version 6.1).
Infection model and preliminary in vivo treatment verification
The neutropenic mouse thigh infection model was used for in vivo studies. Specific-pathogen-free ( In vivo treatment studies were initiated 2 h after bacterial inoculation. To ascertain the effectiveness of colistin and amikacin combinations, colistin was administered intraperitoneally at 5 or 7.5 mg/kg every 12 h, as monotherapy or in combination with amikacin (7.5 mg/kg every 12 h). The mice were euthanized after 24 or 48 h of therapy. Bacterial burden was quantified by cfu determination from posterior thigh homogenates. Groups of two mice (four thigh infections) were included in each dosing regimen. Untreated control mice were similarly sacrificed before treatment and at 0, 24 and 48 h after treatment.
Results
Susceptibility testing
The broth dilution MICs of colistin in the presence of amikacin for the four NDM-5-producing E. coli strains used in this study are shown in Table 1 . Except for E. coli 2121, the strains that harboured bla NDM-5 were susceptible to amikacin. However, the three strains co-carrying bla NDM-5 and mcr-1 (E. coli 1320, 2610 and 2121) exhibited relatively high colistin MICs with and without amikacin (0.5-8 mg/L) compared with E. coli 2630 (0.13-0.5 mg/L; P , 0.05). A concentration-dependent tendency in terms of reduction of colistin MIC was observed with increasing amikacin concentrations from 0 to 4 mg/L. The colistin MICs for the four E. coli strains in combination with 4 mg/L amikacin were decreased to 1/8 or 1/4 of the MIC value of colistin used alone, with the greatest reduction observed for E. coli strain 1320.
Time-kill experiments
The time-kill curves representing log 10 changes in bacterial burden of E. coli strains 2630 and 1320 at low and high inoculum size (10 6 and 10 8 cfu/mL) over 48 h, following exposure to colistin (0-16 mg/L) in the presence of increasing amikacin concentrations (0-4 mg/L) are shown in Figure 1 . The addition of amikacin to colistin considerably improved in vitro bactericidal activity against E. coli strains co-producing NDM-5 and MCR-1 compared with colistin used alone.
An approximately 4.0 log 10 cfu reduction of bacterial burden was observed at a 10 6 cfu/mL inoculum when susceptible E. coli strain 2630 was tested with 1 mg/L colistin for 24 h (Figure 1a) . Neither increasing the colistin concentration nor addition of amikacin augmented the killing effect (Figure 1a-d) . At the higher inoculum size (10 8 cfu/mL), a detectable bactericidal effect on E. coli 2630 was only achieved at elevated colistin concentrations (.8 mg/L), or with colistin plus 4 mg/L amikacin but only with a colistin concentration of 4 mg/L or higher (Figure 1i and l) . However, against the colistin-resistant E. coli 1320, rapid bacterial regrowth occurred after 6 h of exposure to colistin concentrations at 2 mg/L or even higher (Figure 1e ). Interestingly, in combination with 2 or 4 mg/L amikacin, persistent inhibition of bacterial growth was observed at .1 mg/L colistin over 48 h of exposure (Figure 1g and h). Colistin was inactive when used alone against E. coli 1320 at high inoculum size, whereas activity significantly improved when it was combined with .2 mg/L amikacin (Figure 1n-p) .
Similarly, with combinations of .2 mg/L colistin and .1 mg/L amikacin at 10 6 cfu/mL inoculum, both bactericidal activity and sustained inhibition were observed for E. coli 2610 following 48 h of incubation ( Figure S1B -D, available as Supplementary data at JAC Online). Against E. coli 2121, combinations of colistin at 4 mg/L plus amikacin at 1 mg/L, or colistin at 0.5 mg/L plus amikacin at 4 mg/L suppressed bacterial growth for 12 h, but was followed by increased growth (1.1-3.2 log 10 cfu) after 48 h of incubation ( Figure S1F and H) . With the 10 8 cfu/mL inoculum, higher amikacin (.4 mg/L) plus colistin (.1 mg/L) concentrations ( Figure S1P ) or a relatively low amikacin concentration (2 mg/L) in combination with high colistin concentrations (.8 mg/L) ( Figure S1O ) were required to achieve effective bacteriostatic or bactericidal effects. A clear concentration-dependent relationship of colistin activity was observed with increasing amikacin concentrations from 1 to 4 mg/L against all E. coli isolates at both inoculum sizes.
In vitro PD analysis
To ascertain the target therapeutic concentrations of colistin in combination with amikacin against colistin-resistant NDM-5-producing E. coli strains, the Hill-type equation was used for better delineation of the combined antimicrobial effects. The sigmoid E max profiles illustrating the concentration-effect relationship for each E. coli strain are summarized in Figure 2 (r 2 . 0.86), and the corresponding model parameters for the combinations of colistin and amikacin are shown in Table 2 .
For the four E. coli isolates, an evident concentrationdependent decrease in the EC 50 values of colistin was observed at increasing amikacin concentrations from 0 to 4 mg/L (Friedman's ANOVA, P " 0.007; Table 2 ), while no clear trends in E 0 values were detected at both inoculum sizes (P . 0.06). Additionally, with the high initial inoculum, the EC 50 values of colistin appeared to be Colistin/amikacin combination against NDM-5/MCR-1 superbugs JAC considerably larger (1.3-to 20-fold; mean " 6.4) compared with those with the low initial inoculum (F-test; P , 0.001). A similar result was also observed for E max values (1.1-to 6.9-fold) between the different inoculum sizes for all the colistin-resistant E. coli strains.
In vivo treatment verification
The calculated PK parameters for total plasma concentrations of colistin and amikacin are presented in Table S1 . The elimination half-lives of colistin and amikacin were 1.03-1.21 h and 0.95 h, respectively. The body clearance of colistin varied from 4.83 to 6.16 mL/min/kg. The plasma unbound fraction of colistin in neutropenic mice has been previously determined to be ,10%, with a mean of 8.4%, 23 and the corresponding free drug concentration data were generated for PK/PD analysis. Across study strains of E. coli, target values of colistin fAUC/MIC required to achieve 1 log 10 kill and 2 log 10 kill were 11.1 and 14.2 for colistin monotherapy, and 2.79 and 4.56 for colistin/amikacin combinations (Table S2) .
Consequently, when co-dosed with amikacin at 7.5 mg/kg/12 h, colistin dose regimens of 5 and 7.5 mg/kg/12 h are likely to achieve 1-2 log 10 kill (mean fAUC/MIC target values of 2.98 and 4.17, respectively).
The in vivo efficacy of colistin and amikacin administered either as monotherapy or in combination regimens is shown in Figure 3 . Amikacin at 7.5 mg/kg every 12 h inhibited E. coli strain 2630 for 24 h, but regrowth (0.6-1.8 log 10 cfu increase) was observed for infections caused by the other strains at the same amikacin dose. With colistin monotherapy (5 and 7.5 mg/kg every 12 h), heavy growth of the bacterial burden in mouse thighs occurred at both 24 and 48 h for infections caused by the three colistin-resistant strains, while about a 0.3-1.5 log 10 cfu decrease occurred in infection with colistin-susceptible strain 2630 following 24 h of treatment (Figure 3a) . Notably, when colistin was combined with amikacin, all the combination therapies showed efficacies higher than those of each single drug alone, with negative log changes at both 24 and 48 h (1.5-3.8 log 10 cfu reduction; Figure 3a and b), Figure 1 . In vitro time-kill curves of colistin against E. coli 2630 and 1320 in the presence of increasing amikacin concentrations from 0 to 4 mg/L, at low and high inoculum size (10 6 and 10 8 cfu/mL, respectively). The study period was 48 h. Organism concentrations were measured at the times shown. Curves represent the different colistin concentrations (0-16 mg/L), symbols represent means and error bars are standard deviations (n " 3). AMK, amikacin; CST, colistin.
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indicating a significant in vivo antibacterial effect against NDM-5-producing E. coli isolates, including colistin-resistant strains.
Discussion
Carbapenem-resistant E. coli infections represent a major therapeutic challenge and contribute to high mortality rates, especially when the organisms are also resistant to colistin. 24 In such cases, combination therapy might become the best option. Our findings revealed that the addition of amikacin to colistin is effective in vitro and can restore colistin antimicrobial activity against E. coli isolates co-producing NDM-5 and MCR-1; however, this antibiotic combination has been relatively rarely employed in clinical practice. As anticipated, the MCR-1-mediated colistin resistance commonly results in low-level colistin resistance, with only a 2-to 4-fold increase above the susceptibility breakpoint. 4 In the presence of amikacin, all the colistin-resistant E. coli isolates exhibited enhanced susceptibility to colistin, with a significant decrease in colistin MIC compared with the MIC of colistin used alone. In particular, the MICs of colistin in combination with amikacin .2 mg/L were reduced below the current susceptibility breakpoint (2 mg/L) for Enterobacteriaceae. 18 Similarly, the time-kill arrays illustrated an improved colistin activity in combination with increasing amikacin concentrations, with a reduction in EC 50 values in a concentration-dependent manner. These observations indicated that the combination of colistin with amikacin gives in vitro effective bactericidal activity against the low-level colistin-resistant strains.
The in vitro synergy studies can provide a preliminary guidance for rational drug combination, yielding appropriate combination concentrations to exert the optimum microbiological outcomes. However, the in vitro results may not be directly used in the clinic, since in vivo conditions such as dynamic antibiotic concentrations, bacterial virulence and host immune response at the infection site could not be completely mimicked in vitro. 25 Although the synergistic bactericidal activity of colistin in combination with amikacin was shown in vitro, it was necessary to confirm the benefits of Figure 2. Colistin concentration-effect profile for colistin-resistant NDM-5-producing E. coli strains (1320, 2610 and 2121). Synergistic effects of colistin combined with different concentrations of amikacin were addressed at an inoculum of (a) 10 6 cfu/mL and (b) 10 8 cfu/mL. Each symbol represents the Dlog 10 cfu value from a single killing curve. The data points on the y-axis are for the growth control. Data points below the broken line represent killing and points above the broken line represent growth. The line drawn through the data points is the best-fit line based upon the sigmoid E max formula. AMK, amikacin. Colistin/amikacin combination against NDM-5/MCR-1 superbugs JAC these two drugs in combination through in vivo experiments including animal models, especially clinical studies. As far as the combination therapy with intraperitoneal colistin/amikacin is concerned, the in vivo bactericidal activity was promising and definitely superior to colistin or amikacin monotherapy for all isolates tested. Given the limited number of available isolates, only four E. coli strains belonging to different clonal types were evaluated in this study. Sequence typing determined that E. coli strain 1320 can be attributed to a member of the prevalent clone ST648, a new group of MDR virulent strains (from both human patients and animals). 26 Isolates of this clonal complex are commonly associated with NDM, and KPC, ESBLs. 27, 28 Of note, the distribution of ST648 strains among companion animals may be an important source of human infections due to ExPEC and resistant E. coli strains. 14, 29 Despite the similar in vivo efficacies obtained for the isolates in the relatively rare ST156 and ST101 clones, this promising combination regimen needs to be clinically evaluated in infections caused by a larger number of strains.
Several previous investigations have revealed in vitro and in vivo synergistic activities of colistin and amikacin against MDR P. aeruginosa isolates from patients, by both the chequerboard method and patient treatment. 30, 31 Also, a strikingly prolonged post-antibiotic effect (PAE) was observed for P. aeruginosa strains when colistin was combined with amikacin. 32 In addition, Fulnecky et al. 33 reported successful clinical combination therapy with amikacin administered by intravenous and intrathecal routes, along with intravenous colistin, in a case of MDR A. baumannii meningitis. However, owing to the lack of genotype characterization of the strains used, many previous reports are difficult to assess. To the best of our knowledge, we are the first to report augmentation of the antibacterial activity of colistin in combination with amikacin against carbapenem-resistant E. coli strains harbouring the mcr-1 gene, including a strain of the epidemic clonal complex ST648, using the time-kill method, sigmoid E max model and animal treatment experiments as measurements of efficacy. Although the clinical significance of our results has yet to be determined, these observations suggest a useful therapeutic option to fight against the increasingly frequent E. coli strains with resistance to both carbapenems and colistin.
Although some carbapenem-resistant strains of E. coli carrying the mcr-1 gene can be successfully treated with colistin plus amikacin, the mechanism for this kind of synergistic activity remains unclear. It seems likely that the synergy is related to the increased bacterial outer-membrane permeability of colistin. If this is indeed the case, we can assume that colistin might be synergistic with aminoglycosides, including amikacin, which cross the bacterial outer membrane with difficulty, by increasing intracellular aminoglycoside concentration and triggering inhibition of bacterial protein synthesis. Consistent with this view, as reported by Tascini et al., 34 much higher rates of synergistic interaction of a colistin and gentamicin combination were observed in vitro against KPCproducing Klebsiella pneumoniae isolates that included colistinresistant strains. More recently, a similar synergistic effect was observed when colistin was combined with plazomicin, a nextgeneration aminoglycoside. 35 Regardless of the synergistic mechanism, the potential nephrotoxicity in the clinical use of colistin in combination with aminoglycosides should be considered, especially in patients with underlying kidney disease. Generally, in clinical practice, clinicians may be tempted to simply increase the colistin dosage to overcome the attenuated colistin susceptibilities and maximize therapeutic efficacy. Unfortunately, both colistin and amikacin are highly nephrotoxic agents and the potential for renal impairment depends on the drug concentration and daily dose. 36 In patients on renal replacement therapy, an amikacin trough level ,5 mg/L is critical for avoiding kidney dysfunction, 37 and a colistin steadystate plasma concentration (C ss ) of 2 mg/L could be achieved without renal impairment following a dose of colistin at 4.3 MIU every 8 h or 6.3 MIU every 12 h. 38 In this study, rapid bactericidal activity was observed when E. coli strains were exposed to 2 mg/L colistin in combination with 4 mg/L amikacin at an inoculum of 10 6 cfu/mL. The results were in agreement with previous studies, which indicated that a colistin C ss of about 2 mg/L is necessary for effective treatment of bacteria with a colistin MIC of 1 mg/L. 39 However, at an inoculum of 10 8 cfu/mL, i.e. severe infection, killing activity was only achieved at 8 mg/L colistin plus 2 mg/L amikacin or higher. Given the likelihood of renal toxicity, 2 mg/L colistin and 4 mg/L amikacin may be a promising combination to exert the enhanced activity without renal impairment. In addition, it is essential that the colistin dose regimen be adjusted in patients with varying renal functions and morbid states to ensure appropriate drug exposure.
Nevertheless, colistin and amikacin combination therapy may be an appealing option for retaining the clinical utility of colistin against such resistant strains.
In summary, we confirmed that the combination of colistin and amikacin offers substantially augmented in vitro and in vivo bactericidal activity against E. coli strains co-producing NDM-5 and MCR-1. Further multiple-dose PK/PD investigations to optimize dosing regimens with this combination therapy are ongoing in our laboratory. Our findings might constitute an alternative combination regimen for treating infections caused by carbapenem-and colistin-resistant E. coli carrying the mcr-1 gene.
